Alzheimer's

Cassava Sciences Cooperates With DOJ, SEC On Controversial Alzheimer's Drug Investigation
Alzheimer's Drug Trial Results Questioned After 'Damning' FDA Inspection Report
Alzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Others
Alzheimer's Drug Trial Results Questioned After 'Damning' FDA Inspection Report
Alzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Others
FDA Approves Biogen's Alzheimer's Drug: Here Are Other Companies With Treatments In The Pipeline
Tesla, Amazon, Microsoft, Cassava Sciences, Intuitive Surgical: Why These 5 Stocks Are Drawing Investors' Attention Today

Alzheimer's Recent News

Why Biogen Stock Is Up 40% Today
Biogen, Inc. (NASDAQ: BIIB) shares are soaring over 43% to their highest level in about a year in premarket trading Wednesday.
Benzinga's Daily Brief On Trending Tickers For April 19, 2022: Plug Power, Twitter, Cassava Sciences And More
Benzinga’s “Daily Brief On Trending Tickers” features top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news items possibly impacting those stocks.
IGC THC-Drug For Alzheimer's Symptoms Proved Safe & Effective, Pending FDA Approval For More Trials
India Globalization Capital, Inc.
FDA Narrows Label To Recommend Use Of Biogen's Aduhelm In Mild Alzheimer's Patients
Biogen Inc. (NASDAQ: BIIB) shares are lower after the company announced an updated label for its recently-approved Alzheimer's treatment Adu
Biogen Gets FDA Nod For Controversial Alzheimer's Drug; First Treatment Approval For The Disease In 18 Years
After months of wait, Biogen Inc. (NASDAQ: BIIB) has finally achieved success by taking its controversial Alzheimer's treatment past the finish line.
Biogen Surges Higher On Favorable FDA Briefing Doc For Alzheimer's Candidate
Biogen Inc (NASDAQ: BIIB) shares were soaring Wednesday in reaction to an FDA  briefing document released ahead of Friday's Adcom meeting on the investigational Alzheimer's drug aducanumab, an amyloid beta-targeting antibody.
Biogen Soars As FDA Accepts Alzheimer's Drug For Review In 'Next Stage Of Aducanumab Saga'
Biogen Inc's (NASDAQ: BIIB) investigational Alzheimer's drug aducanumab — a drug for which the company halted studies at one point last year — could finally see the light of day.
Biogen Delays Regulatory Filing For Approval Of Alzheimer's Drug, Shares Slump
Biogen Inc (NASDAQ: BIIB) shares were under pressure Wednesday following the release of the biotech's first-quarter report, including the statement that Biogen's BLA filing for its Alzheimer's drug will be delayed.
VTV Therapeutics 'Close To The Finish Line' On What FDA, Diabetes Patients Want: An Adjunct Therapy To Insulin
Biogen's Alzheimer's Drug Has 'Decent Shot' At FDA Approval, Analyst Says
Neurotrope Rips 150% Higher On Improved Alzheimer's Data, NIH Funding
Biogen Analysts Divided Over Alzheimer's Drug Following CTAD Presentation
Biogen's CTAD Presentation On Aducanumab Elicits Mixed Response
Chinese Regulators Tentatively Approve Novel Alzheimer's Drug — The First Since 2003
Cramer Makes The Case Why Biogen's Stock Could Double In Value
Biogen Plans Filing For Failed Alzheimer's Drug After New Analysis; Shares Hit 7-Month High
Why Neurotrope Is Plunging On Heavy Volume
Novartis, Amgen Scrap Pivotal Study Of Alzheimer's Prevention Drug
Biogen Plunges 25% After Company Discontinues Alzheimer's Drug Study
Alzheon's IPO: What You Need To Know
Adam Feuerstein Cautious On Biogen Following Alzheimer's Study
Neurotrope Alzheimer's Candidate Could Generate Revenue Beginning In 2024, Analyst Says
Analyst: Denali Therapeutics' Neuroscience Work Could Lead To Near-Term Upside